Cara Therapeutics Discontinues Clinical Program For Oral Difelikefalin In Notalgia Paresthetica After KOURAGE-1 Study Shows No Meaningful Clinical Benefit At Any Dose Compared To Placebo
Portfolio Pulse from Benzinga Newsdesk
Cara Therapeutics has decided to discontinue its clinical program for oral difelikefalin in treating notalgia paresthetica after the KOURAGE-1 study showed no meaningful clinical benefit at any dose compared to placebo. The company will now explore strategic alternatives.
June 12, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cara Therapeutics has discontinued its clinical program for oral difelikefalin in notalgia paresthetica due to lack of clinical benefit shown in the KOURAGE-1 study. The company will now explore strategic alternatives.
The discontinuation of the clinical program for oral difelikefalin is a significant setback for Cara Therapeutics, as it indicates a failure in a key clinical trial. This is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100